Trial Profile
A Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- Sparing Effects of Mepolizumab in Subjects With Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of Subjects With HES
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 24 Jan 2024
Price :
$35
*
At a glance
- Drugs Mepolizumab (Primary)
- Indications Hypereosinophilic syndrome
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 12 Dec 2023 Results presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 21 Jun 2014 New trial record
- 21 Jun 2014 New trial record